文献速递垂体与肾上腺疾病

整合甲基化组与转录组特征拓展垂体肿瘤的分子分类

Integrating Methylome and Transcriptome Signatures Expands the Molecular Classification of the Pituitary Tumors.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

这项回顾性横断面研究在巴西圣保罗大学里贝朗普雷图医学院对77例垂体肿瘤患者(61%女性,年龄12-72岁)进行甲基化组和转录组分析,无监督层次聚类各识别出3个聚类,分别富集功能性垂体瘤、无功能性垂体瘤以及促肾上腺皮质激素分泌型与无功能性垂体瘤,分子聚类与临床表现、肿瘤侵袭性及2017和2022年WHO分类相关。

要点

  • 甲基化组和转录组无监督层次聚类各识别出3个聚类,分别富集功能性垂体瘤、无功能性垂体瘤及促肾上腺皮质激素分泌型合并无功能性垂体瘤。
  • 基于11个垂体发育/分化相关转录本的聚类支持三种谱系:POU1F1驱动的生长激素细胞腺瘤、TBX19驱动的促肾上腺皮质激素细胞腺瘤和NR5A1驱动的促性腺激素细胞腺瘤,存在罕见例外。
  • 整合甲基化组与转录组特征可对功能性及无功能性垂体瘤进行分类,并与临床表现和肿瘤侵袭性相关。

核心结论

  • 该大型异质性巴西队列证实,整合甲基化组与转录组特征可对功能性垂体瘤和无功能性垂体瘤进行分类,并与临床表现和肿瘤侵袭性相关。
  • 无功能性垂体瘤/促肾上腺皮质激素分泌型腺瘤聚类提示肿瘤异质性,支持2017和2022年WHO定义提出的挑战,即罕见情况下临床表现与垂体谱系标志物之间存在不一致。
  • 公开数据有助于进一步研究验证参与垂体肿瘤发病机制和预后的基因/通路。

研究设计与样本

  • 回顾性横断面研究,纳入巴西圣保罗大学里贝朗普雷图医学院随访的77例垂体肿瘤患者(61%女性,年龄12-72岁),包括功能性垂体瘤(生长激素分泌型n=18,促肾上腺皮质激素分泌型n=14)和无功能性垂体瘤(n=45)。
  • 评估临床病理特征、甲基化组(n=77)和转录组(77例中65例)。

主要发现

  • 甲基化组(n=77)和转录组(77例中65例)的无监督层次聚类分析各识别出3个聚类:一个富集功能性垂体瘤,一个富集无功能性垂体瘤,第三个富集促肾上腺皮质激素分泌型和无功能性垂体瘤。
  • 各组学衍生聚类间比较分别识别出3568个差异甲基化基因和5994个差异表达基因,这些基因彼此相关,并与肿瘤临床表现及2017和2022年WHO分类相关。
  • 基于11个垂体发育/分化相关转录本的聚类支持3个聚类:POU1F1驱动的生长激素细胞腺瘤、TBX19驱动的促肾上腺皮质激素细胞腺瘤和NR5A1驱动的促性腺激素细胞腺瘤,存在罕见例外(NR5A1在少数生长激素分泌型和静默性促肾上腺皮质激素细胞腺瘤中表达;POU1F1在少数促肾上腺皮质激素分泌型腺瘤中表达;TBX19在少数无功能性垂体瘤中表达)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To explore pituitary tumors by methylome and transcriptome signatures in a heterogeneous ethnic population. METHODS: In this retrospective cross-sectional study, clinicopathological features, methylome, and transcriptome were evaluated in pituitary tumors from 77 patients (61% women, age 12-72 years) followed due to functioning (FPT: GH-secreting n = 18, ACTH-secreting n = 14) and nonfunctioning pituitary tumors (NFPT, n = 45) at Ribeirao Preto Medical School, University of São Paulo. RESULTS: Unsupervised hierarchical clustering analysis (UHCA) of methylome (n = 77) and transcriptome (n = 65 out of 77) revealed 3 clusters each: one enriched by FPT, one by NFPT, and a third by ACTH-secreting and NFPT. Comparison between each omics-derived clusters identified 3568 and 5994 differentially methylated and expressed genes, respectively, which were associated with each other, with tumor clinical presentation, and with 2017 and 2022 WHO classifications. UHCA considering 11 transcripts related to pituitary development/differentiation also supported 3 clusters: POU1F1-driven somatotroph, TBX19-driven corticotroph, and NR5A1-driven gonadotroph adenomas, with rare exceptions (NR5A1 expressed in few GH-secreting and corticotroph silent adenomas; POU1F1 in few ACTH-secreting adenomas; and TBX19 in few NFPTs). CONCLUSION: This large heterogenic ethnic Brazilian cohort confirms that integrated methylome and transcriptome signatures classify FPT and NFPT, which are associated with clinical presentation and tumor invasiveness. Moreover, the cluster NFPT/ACTH-secreting adenomas raises interest regarding tumor heterogeneity, supporting the challenge raised by the 2017 and 2022 WHO definition regarding the discrepancy, in rare cases, between clinical presentation and pituitary lineage markers. Finally, making our data publicly available enables further studies to validate genes/pathways involved in pituitary tumor pathogenesis and prognosis.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Silva-Júnior RMPD, Bueno AC, Martins CS, et al. Integrating Methylome and Transcriptome Signatures Expands the Molecular Classification of the Pituitary Tumors. J Clin Endocrinol Metab. 2023. PMID: 36504388. doi:10.1210/clinem/dgac703

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。